Shandong Weigao Group Medical Polymer (OTCMKTS:SHWGF) vs. Sanara MedTech (NASDAQ:SMTI) Head-To-Head Comparison

Shandong Weigao Group Medical Polymer (OTCMKTS:SHWGF) and Sanara MedTech (NASDAQ:SMTI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares Shandong Weigao Group Medical Polymer and Sanara MedTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shandong Weigao Group Medical Polymer	N/A	N/A	N/A
Sanara MedTech	-6.62%	-11.12%	-7.11%

Volatility & Risk

Shandong Weigao Group Medical Polymer has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Institutional and Insider Ownership

8.1% of Sanara MedTech shares are held by institutional investors. 55.2% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Shandong Weigao Group Medical Polymer and Sanara MedTech’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shandong Weigao Group Medical Polymer	$2.02 billion	N/A	$404.68 million	N/A	N/A
Sanara MedTech	$64.99 million	4.31	-$4.30 million	($0.52)	-62.50

Shandong Weigao Group Medical Polymer has higher revenue and earnings than Sanara MedTech.

Analyst Ratings

This is a summary of current ratings and target prices for Shandong Weigao Group Medical Polymer and Sanara MedTech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shandong Weigao Group Medical Polymer	0	0	1	0	3.00
Sanara MedTech	0	0	1	0	3.00

Sanara MedTech has a consensus price target of $44.00, indicating a potential upside of 35.38%. Given Sanara MedTech’s higher probable upside, analysts clearly believe Sanara MedTech is more favorable than Shandong Weigao Group Medical Polymer.

Summary

Shandong Weigao Group Medical Polymer beats Sanara MedTech on 5 of the 9 factors compared between the two stocks.

About Shandong Weigao Group Medical Polymer

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, specialized single-use clinical collection kits, digital products for clinical care, digestive nutrition, and primary care products; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, open and minimally invasive surgical equipment, wound healing dressings, wound suture, wound cleaning, and nonvascular catheter supporting extracorporeal devices. It also provides blood collection, irradiation, storage, separation, and sterilization products; blood collection and blood glucose testing devices; trauma, spinal implant, artificial joints, sports injury, soft tissue repair, reconstruction implant, orthopedic filling, and orthopedic related surgical tools; tumor intervention, vascular intervention, and interventional imaging; and prefilled syringes and pre-filled flush syringes. In addition, the company engages in the manufacturing of implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and X-ray based irradiation machines. Further, it is involved in the finance leasing and factoring business; provision of asset management, enterprise consulting, enterprise management advisory services, logistics and storage, and computer technical services; and sale of electronic products. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.